Enrollment completed in Phase 2 Seabreeze STAT asthma and COPD studies; topline data expected in September 2026, with an FDA Phase 3 discussion planned.
Q2 results and cash position
Connect Biopharma posted a Q2 net loss of USD 17.3 million, or USD 0.27 per share, widening from USD 12.9 million.
License and collaboration revenue rose to USD 2.8 million from USD 48,000, driven by a regulatory milestone net of cost sharing.
R&D expense climbed to USD 16.3 million from USD 8.8 million, reflecting higher rademikibart development spending tied to Seabreeze STAT studies.
Cash, cash equivalents and short-term investments totaled USD 31.5 million; runway expected to extend at least one year.
CNTB•
